Amrize (AMRZ) Q2 FY25 earnings call: guidance and Q&A

How much of the implied H2 EBITDA improvement comes from ASPIRE, and what savings size is visible in the second half?

Management is pleased with ASPIRE's June start and sees it already contributing to H2, but declined to disclose the H2 amount; the program is building toward full run-rate in 2026. Confidence in a stronger H2 also rests on encouraging July volumes and a growing customer backlog.

“We don't disclose how much it will be for the second half of this year, but it will be on the way then to achieve full run rates for 2026.”

asked by Adrian Huerta · answered by Jan Jenisch

Why was first-half cash generation weak (large receivables build), and why does net debt deviate over $1B from the Form 10 pro forma 2024 structure?

Ian attributed weaker YTD free cash flow to a late-Q2 AR build, higher inventory on lower volumes, a cash-tax timing slip from Q4 2024, and higher capex. He said the Form 10 pro forma is the best 2024 figure, that the balance sheet is now fully independent post-bond issuance/exchange, and that mid-year net cash is seasonally lower. He disclosed current net debt of ~$5.3B, guiding to below 1.5x leverage by year-end.

“I think we'll -- the net debt position that we have right now is around $5.3 billion, and we're guiding towards the $1.5 billion by the end of this year.”

asked by Cedar Ekblom · answered by Ian Johnston

Excluding the OX acquisition, what were underlying Envelope price/volume trends, and how much does the 50% Malarkey expansion add to total residential roofing capacity?

Ian said Envelope organic revenue was down ~3% and basically flat on an absolute basis. Jan noted a slow, weather-affected start followed by a meaningful volume rebound in late May/June, especially in commercial roofing (finishing ahead of last year), and highlighted the new fourth Malarkey plant next year as momentum — but did not quantify the total-residential-capacity uplift.

“So in the quarter, our organic growth on revenue was down about 3% on our Building Envelope segment, and we were basically flat on organic growth on absolute growth.”

asked by Pujarini Ghosh · answered by Ian Johnston

Is the ~$40M Q2 corporate cost the new annualized standalone run-rate (x4), is it higher than expected, and can it be reduced?

Ian said the $42M Q2 figure is a little high and at the high end of guidance, expected to phase down in coming quarters. Forecasts will be refined; the $115M full-year additional cost is included in overall guidance.

“The second quarter, $42 million is a little bit high. We would expect that, that could phase out a little bit in the following quarters to come.”

asked by William Jones · answered by Ian Johnston

Why was cement pricing only marginally up versus higher peer readings — any mix or regional effects?

Jan said Amrize has the strongest/highest North American cement pricing and made gains in a challenging market, with cement volumes down 6% and a deliberate value-over-volume focus; he expects pricing to improve as volumes rebound. Aggregates pricing was over 6% in North America on stronger local-market conditions and infrastructure demand.

“You see our volumes were down 6% in Q2. and the market is soft. So we were focusing very much on value for the customers. We didn't have any volume strategy.”

asked by Marcus Cole · answered by Jan Jenisch

Was reroofing positive for both commercial and residential, and how did shingle shipments compare with ARMA industry numbers?

Jan cited positive momentum in commercial roofing — volumes roughly flat through May, Elevate outpacing the market and up low single digits in Q2 — with repair/refurbishment a bright spot. Shingle production was in line with ARMA, with residential repair/refurb impacted by weather and a lighter hail season, but management is positive on H2.

“The shingle production was in line with ARMA.”

asked by Jonathan Bettenhausen · answered by Jan Jenisch

When will the dividend/buyback policy be decided, and what composes the $200B addressable market?

Jan described the $200B as the available market for Amrize's existing products (cement leadership, aggregates follower, strong commercial roofing, low-single-digit shingle share with big growth runway), requiring no new technology and including bolt-on M&A opportunity. Ian reaffirmed priorities of capex first, then M&A, then capital returns — a dividend discussion (likely US-specific) to bring to shareholders in early 2026, with buybacks later. Jan called equity issuance a last resort.

“I would say equity is the last resort. It's expensive.”

asked by Yassine Touahri · answered by Jan Jenisch

Any changes to industry dynamics from the Quikrete-Summit deal, and has it affected Amrize?

Jan demurred, saying he wasn't sure he was competent to answer, viewing it as ongoing industry consolidation (asset/equity swaps) that is probably good for industry structure, and said they will wait to see how it plays out.

“I'm not sure if I'm competent to answer your question.”

asked by Jonathan Bell · answered by Jan Jenisch

Is Amrize still sticking to its 2028 targets (given the share reaction), and what does the ASPIRE program cost?

Jan confirmed confidence in and reaffirmed the midterm/2028 targets set at the March Investor Day despite softer near-term demand, while declining to apply them to the current year. On ASPIRE's cost, he said it is delivered by internal people with an adapted organization and a supply-chain leader from Building Envelope, so there are no extra costs.

“So we don't have extra costs to do this.”

asked by Unknown Analyst · answered by Jan Jenisch